Alia Therapeutics Srl is an Italian biotech start-up whose mission is to develop innovative treatments for incurable genetic diseases using gene editing technology. Our name comes from the Latin word ‘alia’ which means ‘through another way’ indicating the revolutionary nature of our therapeutic approaches.
Alia Therapeutics has been founded in October 2018 by a group of researchers from CIBIO, the biotech department of the University of Trento, who optimised the core CRISPR technologies exploited by the start-up. Six months later Alia received approximately 1.3 million € in seed funding from BiovelocITA and Trentino Invest.
Our research laboratories are currently incubated at CIBIO, while our offices are hosted by HIT – Hub Innovazione Trentino.